Compare fureasu Co., Ltd. with Similar Stocks
Dashboard
1
The company has declared negative results in Jun'2026 after 3 consecutive positive quarters
- NET SALES(Q) At JPY 1,609.13 MM has Fallen at -15.72%
- PRE-TAX PROFIT(Q) At JPY 55.4 MM has Fallen at -64.26%
- NET PROFIT(Q) At JPY 24.5 MM has Fallen at -80.04%
2
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 2,037 Million (Micro Cap)
6.00
NA
0.00%
-0.03
22.52%
0.93
Revenue and Profits:
Net Sales:
1,609 Million
(Quarterly Results - Jun 2026)
Net Profit:
25 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.35%
0%
-7.35%
6 Months
-21.25%
0%
-21.25%
1 Year
-19.42%
0%
-19.42%
2 Years
-57.48%
0%
-57.48%
3 Years
-25.72%
0%
-25.72%
4 Years
-10.93%
0%
-10.93%
5 Years
-36.31%
0%
-36.31%
fureasu Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
17.32%
EBIT Growth (5y)
35.17%
EBIT to Interest (avg)
6.81
Debt to EBITDA (avg)
3.76
Net Debt to Equity (avg)
0.97
Sales to Capital Employed (avg)
1.90
Tax Ratio
20.85%
Dividend Payout Ratio
5.39%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.27%
ROE (avg)
3.35%
Valuation key factors
Factor
Value
P/E Ratio
6
Industry P/E
Price to Book Value
0.94
EV to EBIT
14.49
EV to EBITDA
6.19
EV to Capital Employed
0.95
EV to Sales
0.28
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
6.57%
ROE (Latest)
16.09%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Bearish
No Trend
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
1,609.10
1,474.50
9.13%
Operating Profit (PBDIT) excl Other Income
80.30
201.20
-60.09%
Interest
8.90
11.30
-21.24%
Exceptional Items
0.00
11.20
-100.00%
Consolidate Net Profit
24.50
119.90
-79.57%
Operating Profit Margin (Excl OI)
33.40%
73.30%
-3.99%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 9.13% vs -6.08% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is -79.57% vs 3.81% in Mar 2026
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
7,637.50
7,582.60
0.72%
Operating Profit (PBDIT) excl Other Income
482.70
134.60
258.62%
Interest
100.10
102.30
-2.15%
Exceptional Items
23.00
-1.10
2,190.91%
Consolidate Net Profit
508.90
-244.50
308.14%
Operating Profit Margin (Excl OI)
38.40%
-13.90%
5.23%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 0.72% vs 32.80% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 308.14% vs -519.38% in Mar 2025
About fureasu Co., Ltd. 
fureasu Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






